"We are excited and proud to be part of the rBet v 1 innovative program. As a partner to Stallergenes, CMC is committed to the challenge of producing the world first major recombinant allergens on a large scale" says David Kauffmann, Chairman of CMC Biologics.
ABOUT BIRCH POLLEN ALLERGY
Very common in Northern Europe - and especially Germany, the Netherlands, Norway, Sweden and Switzerland, the prevalence of allergic rhinitis caused by birch pollen exceeds 20% in some large cities.
The birch pollen season is short - lasting just 1 to 2 months - but intense, and precedes the grass pollen season.
ABOUT THE STALAIR(R) PROGRAM
Stalair(R) is the pharmaceutical and clinical development program for immunotherapy being implemented by Stallergenes with a view to obtaining registrations for pharmaceutical products in Europe and, via partnership agreements, with strategic markets outside Europe.
The first tablet resulting from this program, Oralair(R) (grass pollen immunotherapy tablet), is available in Germany for adults and children. This tablet is currently being evaluated in other European countries.
The dust mite immunotherapy tablet, Actair(R) was the subject of a phase IIb/III study in allergic rhinitis in adults during the first half of 2009. A pediatric study has been launched.
Phase IIb/III of the rBet v 1 tablet program has just been completed therefore.
The other allergens concerned by the program are ragweed for the North
American market and Japanese cedar pollen for the Japanese market. All
together, the program covers 80% of the epidemio
Copyright©2009 PR Newswire.
All rights reserved